Compare CMCL & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCL | LCTX |
|---|---|---|
| Founded | 1992 | 1990 |
| Country | Jersey | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 373.1M | 301.7M |
| IPO Year | 2003 | 1996 |
| Metric | CMCL | LCTX |
|---|---|---|
| Price | $17.01 | $1.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $28.00 | $6.25 |
| AVG Volume (30 Days) | 271.7K | ★ 2.1M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | $38.54 | $109.40 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.88 | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $15.85 | $0.93 |
| 52 Week High | $38.75 | $2.09 |
| Indicator | CMCL | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.33 | 37.67 |
| Support Level | N/A | N/A |
| Resistance Level | $20.45 | $1.32 |
| Average True Range (ATR) | 0.87 | 0.06 |
| MACD | -0.14 | -0.01 |
| Stochastic Oscillator | 25.98 | 6.82 |
Caledonia Mining Corp PLC is a gold exploration, development, and mining company. The company's segment includes Blanket, South Africa, Bilboes Oxide mine, and E&E projects. The company generates the majority of its revenue from the Blanket project. The Blanket Mine is located in the south-west of Zimbabwe and operates at a depth of approximately 750 meters below the surface. Its project includes Maligreen and Motapa.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.